Research Reports
MS DUR Board Reports
2021
- March MS-DUR Board Report – HIV PrEP
- March MS-DUR Board Report – Growth Hormone
- March MS-DUR Board Report – Epidiolex
2020
- December MS-DUR Board Report – Naloxone Use Among High-Risk Individuals
- December MS-DUR Board Report – Adult Vaccines
- December MS-DUR Board Report – Adult and Child Core Set
- September MS-DUR Board Report – Sedative Hypnotics
- September MS-DUR Board Report – Opioid Trends
- June MS-DUR Board Report – Cytokine and CAM Antagonist Utilization
- June MS-DUR Board Report – Sickle Cell
- June MS-DUR Board Report – Hep C Overview
- March MS-DUR Board Report – PPI Deprescribing
- March MS-DUR Board Report – HIV Adherence
- March MS-DUR Board Report – Atrial Fibrillation
2019
- December MS-DUR Board Report – TCAs
- December MS-DUR Board Report – HPV Completion Rate
- December MS-DUR Board Report – Buprenorphine Utilization
- September MS-DUR Board Report – Influenza Update
- September MS-DUR Board Report – Synagis Utilization Update
- September MS DUR Board Report DM – Type 2 Diabetes Treatment-Metformin Utilization
- September MS-DUR Board Report – CADD List Utilization
- April MS-DUR Board Report – Makena Update
- April MS-DUR Board Report – Concurrent Use of Opioids and Antipsychotics
- April MS-DUR Board Report – CGRP Inhibitors
- February MS-DUR Board Report – COPD-Opioid Use
- February MS-DUR Board Report – Asthma
2018
- December MS-DUR Board Report – Multiple APs in Children
- December MS-DUR Board Report – Influenza Vaccinations and Treatment
- December MS-DUR Board Report – COPD and GOLD Guidelines
- August MS-DUR Board Report – Opioid Trends
- August MS-DUR Board Report – Migraine
- August MS-DUR Board Report – Codeine-Tramadol Update
- May MS-DUR Board Report – Synagis Utilization Update
- May MS-DUR Board Report – Stimulants and Diagnoses
- May MS-DUR Board Report – Sickle Cell Disease
- May MS-DUR Board Report – Makena Utilization
- February MS-DUR Board Report – PQA Diabetes Recommendations
- February MS-DUR Board Report – Stimulant and Non-Stimulant Utilization
- January MS-DUR Board Report – PPI Deprescribing
2017
- November MS-DUR Board Report – Codeine Tramadol Update
- November MS-DUR Board Report – Cytokine and CAM Antagonist Utilization
- October MS DUR Board Report – Gabapentinoid Use
- October MS-DUR Board Report – Opioid MEDD Level Trend 2016-2017
- July MS-DUR Board Report – Antipsychotic Use in IDD Population
- July MS-DUR Board Report – Codeine Tramadol
- July MS-DUR Board Report – Cytokine and CAM Antagonist Utilization
- April MS-DUR Board Report – Citalopram Utilization and Management
- April MS-DUR Board Report – Hepatitis C Treatments 2015-2017
- April MS-DUR Board Report – Type 2 Diabetes Treatment
- January MS-DUR Board Report – Antidepressant Medication Management in Adults
- January MS-DUR Board Report – Comparison of Pharmacy Programs
- January MS-DUR Board Report Opioid Provider Shopping
2016
- September MS-DUR Board Report – Benzo Utilization for Insomnia
- September MS-DUR Board Report – Buprenorhine-Naloxone Therapy Criteria
- September MS-DUR Board Report – Concomitant Use of Benzo and Opioid
- June MS-DUR Board Report – Preliminary Descriptives from MS-PDMP
- March MS-DUR Board Report – DUR Criteria for Managing Opioid Use and Minimizing Overdose
- March MS-DUR Board Report – Head Lice Treatment
- January MS-DUR Board Report – CDC Guidelines and Opioid DUR Review
- January MS-DUR Board Report – Metabolic Monitoring
- January MS-DUR Board Report – Opioid Overuse Educational Initiatives
2015
- October MS-DUR Board Report – Daraprim Price Increase and Utilization
- October MS-DUR Board Report – Jadenu – Exjade Utilization and Costs
- October MS-DUR Board Report – Mental Health Medication Use in Children Transitioning from FFS to CCO
- July MS-DUR Board Report – Methadone Use
- July MS-DUR Board Report – Synagis Utilization 2014-15 Season
- July MS-DUR Board Report – Triazolam Utilization
- May MS-DUR Board Report – Concomitant Utilization of Naltrexone and Bupropion
- May MS-DUR Board Report – Diabetes Regimens
- May MS-DUR Board Report – Hysingla ER criteria
- May MS-DUR Board Report – Quality Initiative – Follow-up Children Starting ADHD Meds
- May MS-DUR Board Report – Quality Initiative – Metabolic Monitoring Children Antipsychotics
- May MS-DUR Board Report – UPDL Compliance Review
- February MS-DUR Board Report – Hepatitis C Update
- February MS-DUR Board Report – Synagis Update
2014
- November MS-DUR Board Report – Metabolic Monitoring and APS
- November MS-DUR Board Report – Morphine Equivalent Dose Edit
- November MS-DUR Board Report – Oral Contraceptives and Dx
- November MS-DUR Board Report – Weight Loss Clinical Edit for Naltrexone and Bupropion
- August MS-DUR Board Report – Suboxone Utilization in FFS and MSCAN
- August MS-DUR Board Report – Synagis 2014-15 PA Criteria
- August MS-DUR Board Report – Xartemis XR Criteria
- August MS-DUR Board Report – Zohydro ER Criteria
- August MS-DUR Board Report – PDL Compliance Monitoring